CBPartners Publishes Emerging Markets HTA Review Findings in Journal of Pharmaceutical Health Services Research

Share Article

The findings represent some of the latest case-based analyses of HTA assessments conducted on innovative, specialty biopharmaceutical brands in major emerging economies, including Brazil, South Korea, and Taiwan

No single policy intervention has had a more substantial impact on the access and pricing opportunity for new therapeutics than the HTA bodies in these markets.

CBPartners, a global leader in pricing, market access, and health economics / value demonstration in the emerging markets, officially published the findings of a landmark assessment of HTA in the emerging markets. The study was published in the June 2013 issue of the Journal of Pharmaceutical Health Services Research, and uses a case-based approach to systematically assess the process and outcomes of several recent specialty therapeutic product HTA evaluations in Brazil, Korea, and Taiwan.

The study was led by Dr. Rachel Beckerman, Principal of Value Demonstration at CBPartners, who conceptualised the research and analysis with Mr. Cyrus A. Chowdhury, Chief Executive Officer of CBPartners. The research and analysis was conducted with Mr. Shinkyu Park, an Analyst at CBPartners, who has particular expertise on Asia-Pac Pricing and Market Access issues.

“Over the past few years, access and pricing in these emerging markets has become increasingly difficult for manufacturers with innovative, specialty products,” explains Dr. Beckerman. “No single policy intervention has had a more substantial impact on the access and pricing opportunity for new therapeutics than the HTA bodies in these markets. We note that the challenges are not all the same and similar approaches across these emerging markets will not suffice. Each market requires acute responsiveness to the local authorities’ demands.”

“For example, Korea’s HIRA requires many similar evidence and methodological requirements as those needed by England’s NICE,” adds Mr. Park. “However, they go a step further with a more restrictive cost-per-QALY threshold than that seen in England, and additionally throw in international reference pricing to help reduce the total budget impact.”

“We believe that this is just the beginning of more rigid HTA requirements in these emerging economies,” concludes Mr. Chowdhury. “The authorities in these markets will gradually adapt how they wield the power of HTA to a more normative mode. However, the twist is just around the corner as other emerging markets, including China, begin to develop their own HTA systems with unique mandates.”

The complete article can be purchased on the Journal's website, and a similar piece can be found at http://www.cbpartners.com.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical / pharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout over 70 countries. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Cyrus Chowdhury
CB Partners
+1 347 221 9536
Email >
Follow us on
Visit website